NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis $0.71 +0.01 (+1.73%) Closing price 04:00 PM EasternExtended Trading$0.70 -0.01 (-1.47%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Can-Fite BioPharma Stock (NYSE:CANF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Can-Fite BioPharma alerts:Sign Up Key Stats Today's Range$0.67▼$0.7350-Day Range$0.70▼$1.1452-Week Range$0.67▼$3.33Volume496,174 shsAverage Volume216,140 shsMarket Capitalization$2.53 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company Overview Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. Read More Can-Fite BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreCANF MarketRank™: Can-Fite BioPharma scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCan-Fite BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCan-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.Read more about Can-Fite BioPharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.74% of the float of Can-Fite BioPharma has been sold short.Short Interest Ratio / Days to CoverCan-Fite BioPharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Can-Fite BioPharma has recently increased by 353.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.74% of the float of Can-Fite BioPharma has been sold short.Short Interest Ratio / Days to CoverCan-Fite BioPharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Can-Fite BioPharma has recently increased by 353.42%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.52 News SentimentCan-Fite BioPharma has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.Search Interest3 people have searched for CANF on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.80% of the stock of Can-Fite BioPharma is held by insiders.Percentage Held by InstitutionsOnly 21.00% of the stock of Can-Fite BioPharma is held by institutions.Read more about Can-Fite BioPharma's insider trading history. Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CANF Stock News HeadlinesCan-Fite BioPharma Ltd.: Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular DementiaJuly 28 at 6:52 PM | finanznachrichten.deBreakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular DementiaJuly 28 at 6:52 PM | finance.yahoo.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 29 at 2:00 AM | Porter & Company (Ad)Can-Fite BioPharma Ltd. Announces $5.0 Million Public Offering with Potential for Additional $10.0 Million in Gross ProceedsJuly 28 at 12:36 PM | quiverquant.comQCan-Fite Announces Up To $15.0 Million Public OfferingJuly 28 at 12:24 PM | globenewswire.comCan-Fite BioPharma’s Piclidenoson Shows Promise in Vascular Dementia TreatmentJuly 28 at 7:47 AM | tipranks.comBreakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular DementiaJuly 28 at 7:00 AM | globenewswire.comCANF Can-Fite BioPharma Ltd. - Seeking AlphaJune 27, 2025 | seekingalpha.comSee More Headlines CANF Stock Analysis - Frequently Asked Questions How have CANF shares performed this year? Can-Fite BioPharma's stock was trading at $1.6250 at the start of the year. Since then, CANF stock has decreased by 56.1% and is now trading at $0.7135. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) released its earnings results on Tuesday, November, 30th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($0.90) by $1.00. The firm had revenue of $0.25 million for the quarter. When did Can-Fite BioPharma's stock split? Shares of Can-Fite BioPharma reverse split on Monday, January 9th 2023.The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Can-Fite BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE). Company Calendar Last Earnings11/30/2021Today7/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:CANF CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees8Year FoundedN/APrice Target and Rating Average Price Target for Can-Fite BioPharma$14.00 High Price Target$18.00 Low Price Target$10.00 Potential Upside/Downside+1,863.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick RatioN/A Sales & Book Value Annual Sales$674 thousand Price / Sales3.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book0.41Miscellaneous Outstanding Shares3,540,000Free FloatN/AMarket Cap$2.52 million OptionableNot Optionable Beta1.11 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:CANF) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.